Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study by Gaspar, Nathalie, MD, Venkatramani, Rajkumar, MD, Hecker-Nolting, Stefanie, MD, Melcon, Soledad Gallego, Prof, Locatelli, Franco, Prof, Bautista, Francisco, MD, Longhi, Alessandra, MD, Lervat, Cyril, MD, Entz-Werle, Natacha, Prof, Casanova, Michela, MD, Aerts, Isabelle, MD, Strauss, Sandra J, MD, Thebaud, Estelle, MD, Morland, Bruce, Prof, Nieto, Adela Cañete, MD, Marec-Berard, Perrine, MD, Gambart, Marion, MD, Rossig, Claudia, Prof, Okpara, Chinyere E, PhD, He, Cixin, PhD, Dutta, Lea, PharmD, Campbell-Hewson, Quentin, MBChB

Get full text

A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in... by Makker, Vicky, MD, Colombo, Nicoletta, MD, Herráez, Antonio Casado, MD, Santin, Alessandro, MD, Colomba, Emeline, MD, Miller, David, MD, FACOG, FACS, Fujiwara, Keiichi, MD, PhD, Pignata, Sandro, MD, PhD, Baron-Hay, Sally, MBBS, FRACP, Ray-Coquard, Isabelle, Prof, Shapira-Frommer, Ronnie, MD, Ushijima, Kimio, Sakata, Jun, MD, PhD, Yonemori, Kan, MD, Kim, Yong Man, MD, Guerra, Eva, MD, Sanli, Ulus, MD, McCormack, Mary, PhD MBBS FRCR, Huang, Jie, Smith, Alan, Keefe, Stephen, MD, Dutta, Lea, PharmD, Orlowski, Robert, MD, Lorusso, Domenica, MD, PhD

Get full text